On 7 February 2018, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.
Her talk was part of the Simons Foundation Autism Research lecture series.
About the Lecture
Autism has well-established roots in disruptions during the development of neural networks. Functional neuroimaging methods, such as electroencephalography (EEG), can measure these brain changes, with such measurements serving as robust “biomarkers” of the condition. Studies of autism biomarkers can enhance our ability to predict atypical development early in infancy and can improve both the selection of trial participants and quantification of brain changes with treatment in clinical trials. However, autism biomarker studies face many challenges, from methods in data collection to the generalizability of findings to the broader autism spectrum.
In this lecture, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.
